Clinical research is at a crossroads. The technology exists, the data is available, and the ambition is clear, but adoption of truly integrating Artificial Intelligence (AI) and data-driven trials often stalls due to risk, trust, and organizational inertia. In this episode, we explore how innovative approaches are reshaping the future of clinical trials.
About this episode
In this episode of The Future Prescription: Inside the Trends, Steve Kundrot, Chief Operating Officer of TriNetX, engages in a thought-provoking conversation with Guillaume Carbonneau, Vice President of Operational Data Insights at Novo Nordisk. They examine the transformative potential of data and AI in clinical trials and explore Trend #1, “Precision by Numbers: Data-Driven Clinical Trials,” and Trend #3, “AI Meets RWD: Revolutionizing Drug Development and Research” from The Future Prescription report.
Note: Guillaume Carbonneau is not an official spokesperson for Novo Nordisk. His comments reflect his personal perspective and experience, informed by his role at the company.
Featuring Industry Leaders:
Moderator: Steve Kundrot, Chief Operating Officer, TriNetX
Steve is a technology and business leader with over 20 years of experience in clinical research, health analytics, consulting and software development. Prior to TriNetX, Steve built and led engineering teams at Perceptive Informatics and PAREXEL. Before that, Steve was a technology consultant for several Fortune 1000 and startup companies and co-founder of an internet infrastructure company. Steve has a BS in Engineering from Cornell University and an MBA from Babson College.
Guillaume Carbonneau, Vice President of Operational Data Insights, Novo Nordisk
Guillaume Carbonneau is an accomplished leader in operational insights, specializing in clinical development business problem-solving and decision-making. With two decades in the pharmaceutical industry, he has spent the last 10 years leveraging technology to enhance patient outcomes and foster innovation.
As Vice President of Operational Data Insights at Novo Nordisk, he leads a transformative team focused on data-driven decision-making and developing the StudyHub platform. His team’s expertise optimizes clinical trial design, planning, forecasting and execution, ensuring AI-generated insights have real-world impact. They are fostering a culture where data drives decisions across the portfolio.
Before Novo Nordisk, Guillaume was Head of Health Data Insights & Design at Novartis. There, he utilized cross-disciplinary experience to develop data-driven methodologies, incorporating profiling methodologies and design thinking to enhance product desirability. His collaborative approach led to innovative healthcare solutions in partnership with external stakeholders, underlining his commitment to transforming clinical practices.
Guillaume’s passion for technology, data and AI, continues to drive innovation in data insights, creating actionable outcomes that deliver tangible results.
Guillaume is not an official spokesperson for Novo Nordisk, and his comments reflect his personal perspective and experience, informed by his role at the company.